An announcement from Disc Medicine ( (IRON) ) is now available.
Disc Medicine, a biopharmaceutical company, unveiled promising interim results from its Phase 1b trial of DISC-0974 at the ASN Kidney Week 2024. The study showcased significant improvements in anemia markers for patients with non-dialysis-dependent chronic kidney disease (NDD-CKD), demonstrating substantial reductions in hepcidin levels and increases in hemoglobin. DISC-0974’s safety and tolerability were confirmed, highlighting its potential as a treatment for anemia linked to various chronic conditions. These findings suggest DISC-0974’s broader applicability in addressing anemia associated with inflammatory diseases.
For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
